- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc stock price live, this page displays NASDAQ LXRX stock exchange data. View the LXRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lexicon Pharmaceuticals Inc real time stock price chart below.
What Is the Lexicon Pharmaceuticals Inc Stock Price Today?
The Lexicon Pharmaceuticals Inc stock price today is 1.690.
What Is the Stock Symbol for Lexicon Pharmaceuticals Inc?
The stock symbol for Lexicon Pharmaceuticals Inc is "LXRX."
What Stock Exchange Does Lexicon Pharmaceuticals Inc Trade On?
Lexicon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Lexicon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Lexicon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LXRX quote. (ISIN: US5288723027)
What Is the Lexicon Pharmaceuticals Inc Stock Price Today?
The Lexicon Pharmaceuticals Inc stock price today is 1.690.
What Is the Stock Symbol for Lexicon Pharmaceuticals Inc?
The stock symbol for Lexicon Pharmaceuticals Inc is "LXRX."
What Stock Exchange Does Lexicon Pharmaceuticals Inc Trade On?
Lexicon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Lexicon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Lexicon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LXRX quote. (ISIN: US5288723027)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.670
1.760
52 wk Range
0.514
1.950
LXRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.6701.760
52 wk Range
0.5141.950
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LXRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
3.360
Upside
+98.82%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
- Form DEF 14A LEXICON PHARMACEUTICALS For: 17 March
- Investing.com
- Form DEF 14A LEXICON PHARMACEUTICALS For: 17 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Lexicon Pharmaceuticals beat Q4 2025 expectations with EPS of -$0.04 vs. -$0.07 forecast and revenue of $5.5M vs. $3.92M projected.
- Company achieved 54.1% improvement in net loss per share through cost reductions: R&D expenses down 57.7%, SG&A down 72.8% year-over-year.
- Stock declined 4.29% to $1.56 in pre-market despite earnings beat, following 385% gain over past year; InvestingPro suggests slight overvaluation.
- 2026 guidance projects operating expenses of $100M-$110M with focus on cardiometabolic programs and Zynquista resubmission for Type 1 diabetes.
- CEO highlighted strengthened balance sheet and strategic repositioning; company completed successful capital raise post-year-end to fund development.
Last Updated: 03/05/2026, 10:34 PM
Read Full TranscriptCompare LXRX to Peers and Sector
Metrics to compare | LXRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLXRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.2x | −2.2x | −0.5x | |
PEG Ratio | −0.18 | −0.05 | 0.00 | |
Price/Book | 6.7x | 2.4x | 2.6x | |
Price / LTM Sales | 14.4x | 50.6x | 3.2x | |
Upside (Analyst Target) | 36.1% | 206.1% | 47.4% | |
Fair Value Upside | Unlock | 7.0% | 6.9% | Unlock |
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3.360
(+98.82% Upside)
Earnings
Latest Release
Mar 05, 2026
EPS / Forecast
-0.04 / -0.07
Revenue / Forecast
5.5M / 3.92M
People Also Watch
FAQ
What Is the Lexicon (LXRX) Stock Price Today?
The Lexicon stock price today is 1.690 USD.
What Stock Exchange Does Lexicon Trade On?
Lexicon is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Lexicon?
The stock symbol for Lexicon is "LXRX."
What Is the Lexicon Market Cap?
As of today, Lexicon market cap is 716.020M USD.
What Is Lexicon's Earnings Per Share (TTM)?
The Lexicon EPS (TTM) is -0.139.
When Is the Next Lexicon Earnings Date?
Lexicon will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is LXRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Lexicon Stock Split?
Lexicon has split 1 times.
How Many Employees Does Lexicon Have?
Lexicon has 81 employees.
What is the current trading status of Lexicon (LXRX)?
As of Apr 28, 2026, Lexicon (LXRX) is trading at a price of 1.690 USD, with a previous close of 1.690 USD. The stock has fluctuated within a day range of 1.670 USD to 1.760 USD, while its 52-week range spans from 0.514 USD to 1.950 USD.
What Is Lexicon (LXRX) Price Target According to Analysts?
The average 12-month price target for Lexicon is 3.360 USD, with a high estimate of 6 USD and a low estimate of 1 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +98.82% Upside potential.
What Is the LXRX Premarket Price?
LXRX's last pre-market stock price is 1.710 USD. The pre-market share volume is 20.000, and the stock has decreased by 0.020, or 1.180%.
What Is the LXRX After Hours Price?
LXRX's last after hours stock price is 1.699 USD, the stock has decreased by 0.009, or 0.550%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.